Benson Kaluba

Dr. Benson Kaluba

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2025 in Surgical Oncology
Verified
Journal Article
Open access
AHAoi Hayasaki
Aoi Hayasaki
SMShugo Mizuno
Shugo Mizuno
BKBenson Kaluba
Benson Kaluba
YSYuki Segi
Yuki Segi
HKHaruna Komatsubara
Haruna Komatsubara
MKMasashi Kishiwada
Masashi Kishiwada
In this study, we present our institution's treatment outcomes and surgical strategies for patients with localized pancreatic ductal adenocarcinoma (PDAC). The study retrospectively reviewed clinical data of 397 patients with localized PDAC who were enrolled in a gemcitabine and S-1 based chemoradiotherapy (GS-CRT) protocol between September 2011 and March 2023. Following GS-CRT, pancreatectomy was performed and concomitant vascular resection with subsequent reconstruction was done, if required, in order to achieve R0 resection margins. From the 397 patients, 366 (92.2 %) completed the GS-CRT. A total of 359 patients were adequately re-evaluated after GS-CRT and categorized as having resectable (R; n = 77), borderline resectable with superior mesenteric vein/portal vein involvement (BR-PV; n = 40), borderline resectable with arterial involvement (BR-A; n = 94), or unresectable locally advanced (UR-LA; n = 148) tumors, respectively. From these, 202 patients with R (n = 63), BR-PV (n = 31), BR-A (n = 56) and UR-LA (n = 52) PDAC underwent curative-intent pancreatectomy. The R0 resection rates and median survival times for disease-specific survival (DSS) according to resectability were favorable: 98.4 %, 93.5 %, 92.9 %, and 80.8 %, and 62.7, 66.1, 41.8, and 36.2 months, respectively. Prognostic factors for DSS among the 202 resected patients included performance status, pre-operative carbohydrate antigen 19-9 and carcinoembryonic antigen serum levels, pre-operative tumor resectability, pathological T factor and receipt of adjuvant chemotherapy. In the resected UR-LA patients, adjuvant chemotherapy was a significant prognostic factor of survival outcomes. GS-CRT followed by pancreatectomy is feasible and a beneficial treatment strategy for PDAC. Therefore, a safe and reliable surgical approach that ensures R0 resection margins and enables subsequent adjuvant chemotherapy is essential.

20 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MKMasashi Kishiwada
Masashi Kishiwada
SMShugo Mizuno
Shugo Mizuno
AHAoi Hayasaki
Aoi Hayasaki
BKBenson Kaluba
Benson Kaluba
TFTAKEHIRO FUJII
TAKEHIRO FUJII
NKNaohisa Kuriyama
Naohisa Kuriyama
Background: This study aimed to assess the safety and efficacy of gemcitabine plus S-1-based chemoradiotherapy (GS-CRT) among patients with locally advanced pancreatic ductal adenocarcinoma (PDAC), especially among those with unresectable locally advanced (UR-LA) cases. Methods: A total of 351 consecutive PDAC patients were enrolled and prognostic predictors of disease-specific survival (DSS) were identified. Results: The treatment completion rate was 98.9% and Grade 3 or higher adverse events occurred in 181 cases (51.6%). Among 319 re-evaluated patients, pancreatectomy was performed in 184 (57.7%). Based on resectability, the 5-year DSS rates for the entire cohort were 39.6% (R), 43.8% (BR-PV), 21.2% (BR-A) and 13.3% (UR-LA), while the predictors of DSS were performance status (PS), hemoglobin (Hb) level, celiac artery (CA) involvement of ≥180 degrees and JPS 8th T category. In the resected cases, the predictors of DSS were preoperative PS, preoperative CA19-9 level, preoperative JPS-T factor, degree of histological response and adjuvant chemotherapy. In UR-LA resected patients, preoperative prognostic nutritional index (PNI), absence of pathological venous invasion and adjuvant chemotherapy were predictors of DSS. Conclusions: Even though Grade 3 or higher adverse events were encountered in about half of the cases, they were uneventfully managed. Therefore, GS-CRT is safe and highly tolerable with potential to improve patients‘ prognosis. Preoperative PS, CA19-9 levels and histological response are important prognostic factors, as well as adjuvant therapy. In UR-LA patients, prognostic nutritional index (PNI) and adjuvant chemotherapy were important for curative intent surgery.

22 January 2025 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
PDF file
BKBenson Kaluba
Benson Kaluba
NKNaohisa Kuriyama
Naohisa Kuriyama
TSTatsuya Sakamoto
Tatsuya Sakamoto
HKHaruna Komatsubara
Haruna Komatsubara
KMKoki Maeda
Koki Maeda
SMShugo Mizuno
Shugo Mizuno
Background The study aimed at assessing whether long-term survival outcomes were different based on tumor location in pancreatic ductal adenocarcinoma (PDAC) patients who underwent pancreatectomy following neoadjuvant chemoradiotherapy (CRT). Methods Following CRT, resection rate was 60.5% (286/473) and the resected patients had pancreatic head (n = 218), body (n = 34) and tail (n = 34) tumors. Survival analyses were conducted, independent predictors of disease-free survival (DFS) and overall survival (OS) were identified, and then survival outcomes were stratified by the predictors of DFS and OS. Results Resection rates were; 64.7% (head) vs. 46.6% (body) and 54.0% (tail) cases, p = 0.009. Among these cases, pancreatic head patients exhibited a higher incidence of initial clinical stage 3 tumors; 48.2% (head) vs. 29.4% (body) and 0% (tail) cases, p < 0.001 with more unresctable-locally advanced tumors; 22.0% (head) vs. 11.8% (body) and 0% (tail), p < 0.001, but demonstrated a better response to CRT; Evans grades 3/4 in 49.1% (head) vs. 23.5% (body) and 26.5% (tail), p = 0.012. Five-year DFS rates were; 19.9% (head) vs. 11.8% (body) vs. 24.6% (tail), p = 0.565 and OS rates; 25.4% (head) vs. 27.7% (body) vs. 32.0% (tail), p = 0.341. Significant predictors of DFS and OS included post-CRT CA19-9 levels, tumor differentiation, resection margins and pathological portal vein invasion. Based on these predictors, survival outcomes were also comparable. Pathological nodal invasion influenced DFS, while pathological stage impacted OS. Conclusion Pancreatic head patients had the best resection rate and long-term survival outcomes were comparable, attributable to the better response to CRT by pancreatic head than the body and tail PDAC patients.

10 April 2025 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
BKBenson Kaluba
Benson Kaluba
NKNaohisa Kuriyama
Naohisa Kuriyama
MNMotonori Nagata
Motonori Nagata
TITakahiro Ito
Takahiro Ito
AHAoi Hayasaki
Aoi Hayasaki
SMShugo Mizuno
Shugo Mizuno
Aim: To assess the ability of a new severity‐based tumor‐superior mesenteric/portal vein interface criteria to predict survival outcomes in pancreatic ductal adenocarcinoma patients undergoing pancreaticoduodenectomy after neoadjuvant chemoradiotherapy (CRT).Methods: Two hundred and twenty‐six post‐CRT patients were enrolled and 22 had no tumor‐SMV/PV contact, while the remaining 204 had. Based on correlation with overall survival (OS), circumferential (210 degrees) and contact length (25 mm) interface cut‐off values were identified, then used to formulate no tumor‐SMV/PV contact, non‐severe, and severe interface criteria. Significant predictors of disease‐free (DFS) and OS were identified.Results: The severe group had significantly more UR‐LA, cStage 3 cases, longer operation times, more intra‐operative blood loss, R1 resection, and pPV invasion cases than the no tumor‐contact and non‐severe interface groups (p < 0.001). Median DFS were 37.7 (no tumor‐contact), 17.0 (non‐severe), and 5.2 (severe) months and OS was 56.7, 29.9, and 12.0. Among tumor‐contact patients, the interface criteria (84.7%) had a better specificity in predicting pPV invasion than tumor‐contact length (76.9%) and tumor‐circumferential interface (73.8%). Those with pPV invasion had shorter DFS (16.7 vs. 5.7) and OS (28.3 vs. 13.6) than those without pPV invasion. Significant independent predictors of both DFS and OS were the interface criteria, resection margins, and pPV invasion. Clinical and pathological lymph node involvement also influenced DFS, while circumferential interface and pathological tumor stage also impacted OS.Conclusion: Patients can be stratified as no tumor‐contact, non‐severe, or severe interface cases and the criteria might be useful in preoperatively predicting not only survival but also intra‐operative outcomes and pPV invasion.